VERU
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Veru advanced oral sabizabulin toward a planned Phase 2 trial after positive preclinical results showed potent anticancer activity in RASONQUE-resistant pancreatic cancerSep 8, 2026
- Veru received a U.S. patent notice of allowance for methods of using enobosarm with semaglutide for quality weight lossAug 4, 2026
- Veru completes enrollment in Phase 2b trial of enobosarm plus semaglutide for high-quality weight lossJul 27, 2026
- Veru enrolled the first patient in the Phase 2b PLATEAU trial testing enobosarm combined with semaglutide for high-quality weight lossMar 9, 2026
- Veru announces successful FDA meeting providing regulatory clarity for Enobosarm for muscle preservation in combination with GLP-1 RA for greater weight loss in obesity treatmentSep 23, 2025